Stock Events

Bone Biologics 

$1.99
18
-$0.1-4.78% Friday 20:00

Statistics

Day High
2.12
Day Low
1.58
52W High
11.76
52W Low
1
Volume
459,317
Avg. Volume
2,652,486
Mkt Cap
2.19M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-29.33
-19.55
-9.78
0
Expected EPS
-7.6
Actual EPS
-1.31

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLG. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stryker
SYK
Mkt Cap129.88B
Stryker Corporation is a leading medical technology company that offers a range of orthopedic products, competing directly with Bone Biologics in the bone repair and regeneration market.
Zimmer Biomet
ZBH
Mkt Cap22.73B
Zimmer Biomet Holdings, Inc. specializes in musculoskeletal healthcare, offering products that compete in the orthopedic sector, similar to Bone Biologics' offerings.
Medtronic
MDT
Mkt Cap101.91B
Medtronic plc provides medical technologies, services, and solutions, including bone healing and regeneration products, making it a competitor in the same space as Bone Biologics.
Boston Scientific
BSX
Mkt Cap114.03B
Boston Scientific Corporation offers products in various medical fields, including orthopedic surgery, competing with Bone Biologics in areas like bone growth and repair.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers a wide range of orthopedic products, directly competing with Bone Biologics in the field of bone health and regeneration.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc., while primarily known for its biopharmaceutical products, has ventured into cell therapy, which could potentially compete with Bone Biologics' regenerative medicine approaches.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc., with its broad range of healthcare products, has the potential to compete in the orthopedic and regenerative medicine space, overlapping with Bone Biologics' market.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including treatments that could compete with Bone Biologics in bone health and regeneration.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. focuses on human therapeutics, including osteoporosis treatment and bone health products, making it a competitor in the bone regeneration market alongside Bone Biologics.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Other Services (except Public Administration)
Professional Organizations
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Show more...
CEO
Employees
2
Country
US
ISIN
US0980703039

Listings

XNAS
US
BBLGW
XNAS
US
BBLG